Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON D FERREIRA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1194952929
CMS profile
235381
Location
PROVIDENCE, RI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$195.57

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Grant $100.00 1
Food and Beverage $95.57 6

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $100.00 1
PFIZER INC. $60.46 4
AbbVie, Inc. $35.11 2

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON D FERREIRA

NPI 1194952929 · CMS profile ID 235381

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

PROVIDENCE, RI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194952929?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON D FERREIRA, NPI 1194952929, CMS profile ID 235381. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194952929?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JASON D FERREIRA, NPI 1194952929, CMS profile ID 235381. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194952929?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JASON D FERREIRA, NPI 1194952929, CMS profile ID 235381, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194952929?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $195.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $19.3412/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648218061 CMS
AbbVie, Inc. $15.7711/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648218059 CMS
PFIZER INC. $15.2609/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672955309 CMS
PFIZER INC. $16.2505/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672010847 CMS
PFIZER INC. $12.3004/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671962895 CMS
Boston Scientific Corporation $100.0003/27/2019 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663133745 CMS
PFIZER INC. $16.6503/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671924069 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $195.57 7
PY2020 $194.20 10
PY2021 $101.84 5
PY2022 $361.51 22
PY2023 $330.62 27
PY2024 $206.59 3
PY2025 $101.86 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $346,315.00 113
PY2023 Principal investigator $7,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,540.00 11/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,177.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288381
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,177.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288383
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288399
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,177.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288401
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,177.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288415
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,177.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,177.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288423
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288425
Principal investigator 1 Genentech, Inc. $2,379.00 11/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287959
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287963
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287965
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $878.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,358.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223287987
Principal investigator 1 Genentech, Inc. $2,848.00 10/09/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663420
Principal investigator 1 F. Hoffmann-La Roche AG $2,540.00 08/26/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223283997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223283999
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284001
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284005
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284007
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284057
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 08/11/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284059
Principal investigator 1 F. Hoffmann-La Roche AG $5,122.00 08/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662921
Principal investigator 1 F. Hoffmann-La Roche AG $3,188.00 07/31/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211662917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282696
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282698
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282700
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282702
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282704
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282708
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282714
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282716
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282718
Principal investigator 1 Genentech, Inc. $10,235.00 06/19/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663087
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281484
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281486
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281488
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281490
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281492
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,318.00 06/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281494
Principal investigator 1 Genentech, Inc. $4,296.00 05/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663105
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279532
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279534
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279536
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279538
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279540
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279542
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279544
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279546
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279548
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279550
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279552
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279554
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279556
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279558
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279560
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279562
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279564
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279634
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279636
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279638
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279674
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279676
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279678
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279680
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279682
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279684
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279686
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279688
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279690
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279692
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279694
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279696
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279698
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279700
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279702
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279704
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279706
Principal investigator 1 Genentech, Inc. $2,922.00 05/08/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663152
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,292.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278202
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278204
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,099.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278208
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,512.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,337.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278212
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278294
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,642.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278296
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,863.00 04/18/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278298
Principal investigator 1 Genentech, Inc. $18,040.00 04/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663091
Principal investigator 1 Genentech, Inc. $1,400.00 04/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663138
Principal investigator 1 Genentech, Inc. $2,000.00 04/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663163
Principal investigator 1 Genentech, Inc. $3,447.00 03/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663079
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $836.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276597
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $836.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276599
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276653
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276655
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,106.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276661
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $836.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY GASTROENTEROLOGY LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276663
Principal investigator 1 Genentech, Inc. $10,883.00 03/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211663071